| 2024 |
Eficacia de la
infusión extendida de los antibióticos B-lactámicos en el tratamiento de
la neutropenia febril en los pacientes hematológicos
|
19.017 |
BEATLE |
RESULTADOS |
Enfermedades Infecciosas |
| 2024 |
Efficacy and
safety of a structured de-escalation from antipseudomonal β-lactams in
bloodstream infections due to Enterobacterales (SIMPLIFY): an
open-label, multicentre, randomised trial
|
16.001 |
SIMPLIFY |
RESULTADOS |
Enfermedades Infecciosas |
| 2023 |
Efficacy and
safety of different antimicrobial DURATions for the treatment of
Infections associated with Osteosynthesis Material implanted after long
bone fractures (DURATIOM): Protocol for a randomized, pragmatic
trial
|
21.012 |
DURATIOM |
PROTOCOLO |
Enfermedades Infecciosas |
| 2023 |
Randomised,
open-label, non-inferiority clinical trial on the efficacy and safety of
a 7-day vs 14-day course of antibiotic treatment for uncomplicated
enterococcal bacteraemia: the INTENSE trial protocol
|
21.032 |
INTENSE |
PROTOCOLO |
Enfermedades Infecciosas |
| 2023 |
Short-course antibiotic
regimen
compared to conventional antibiotic treatment for gram-positive cocci
infective endocarditis: randomized clinical trial (SATIE)
|
20.006 |
SATIE |
PROTOCOLO |
Enfermedades Infecciosas |
| 2023 |
Cloxacillin plus
fosfomycin versus cloxacillin alone for methicillin-susceptible
Staphylococcus aureus bacteremia: a randomized trial
|
19.016 |
SAFO |
RESULTADOS |
Enfermedades Infecciosas |
| 2022 |
Double-blind placebo-controlled randomized clinical trial
to assess the efficacy of montelukast in mild to moderate respiratory
symptoms of patients with long COVID: E-SPERANZA COVID Project study
protocol
|
21.040 |
E-SPERANZA COVID |
PROTOCOLO |
Enfermedades Infecciosas |
| 2022 |
Early Use of Sarilumab in Patients Hospitalized with
COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR
Randomized Clinical Trial
|
20.019 |
SARICOR |
RESULTADOS |
Enfermedades Infecciosas |
| 2022 |
Study protocol
for a randomized clinical trial to assess 7 versus 14-days of treatment
for Pseudomonas aeruginosa bloodstream infections (SHORTEN-2
trial).
|
21.028 |
SHORTEN II |
PROTOCOLO |
Enfermedades Infecciosas |
| 2022 |
Seven-versus 14-day
course of antibiotics for the treatment of bloodstream infections by
Enterobacterales: a randomized, controlled trial
|
15.011 |
SHORTEN I |
RESULTADOS |
Enfermedades Infecciosas |
| 2022 |
Effectiveness of Fosfomycin for
the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary
Tract Infections A
Randomized Clinical Trial
|
14.005 |
FOREST |
RESULTADOS |
Enfermedades Infecciosas |
| 2021 |
Clinical
effectiveness and bacteriological eradication of three different
Short-COurse antibiotic regimens and single-dose fosfomycin for
uncomplicated lower Urinary Tract infections in adult women (SCOUT
study): study protocol for a randomised clinical trial
|
21.026 |
SCOUT |
PROTOCOLO |
Enfermedades Infecciosas |
| 2021 |
Vaccination adjuvated against hepatitis B in Spanish
National Healthcare System
(SNS) workers typed as non-responders to conventional vaccines
|
17.027 |
VACANTIB |
RESULTADOS |
Enfermedades Infecciosas |
| 2021 |
Temocillin
versus
meropenem for the
targeted treatment of bacteraemia due to third-generation
cephalosporin-resistant Enterobacterales (ASTARTÉ): protocol for a
randomised, pragmatic
trial
|
20.004 |
ASTARTE |
PROTOCOLO |
Enfermedades Infecciosas |
| 2020 |
Efficacy and safety of early treatment with sarilumab in
hospitalised adults with COVID-19 presenting cytokine release syndrome
(SARICOR STUDY): protocol of a phase II, open-label, randomised,
multicentre, controlled clinical trial
|
20.019 |
SARICOR |
PROTOCOLO |
Enfermedades Infecciosas |
| 2020 |
Randomised
multicentre clinical trial to evaluate voriconazole pre-emptive
genotyping strategy in patients
with risk of aspergillosis: vorigenipharm study protocol
|
19.002 |
VORIGEPHARM |
PROTOCOLO |
Enfermedades Infecciosas |
| 2019 |
Effectiveness of antitussives, anticholinergics or honey
versus usual care in adults with uncomplicated acute bronchitis: a study
protocol of an open randomised clinical trial in primary care
|
17029 |
AB4T |
PROTOCOLO |
Enfermedades Infecciosas |
| 2019 |
Opportunities for antibiotic optimisation and outcome
improvement in patients
with negative blood cultures: study protocol for a cluster-randomised
crossover trial, the
NO-BACTstudy
|
18.010 |
NO BACT |
PROTOCOLO |
Enfermedades Infecciosas |
| 2018 |
Population
pharmacokinetics and
pharmacodynamics of fosfomycin in non-critically ill patients with
bacteremic urinary infection
caused by multidrug-resistant Escherichia coli
|
14.005 |
FOREST |
RESULTADOS |
Enfermedades Infecciosas |
| 2018 |
Efficacy
and safety of the
combination of reduced duration prophylaxis followed by immuno-guided
prophylaxis to prevent
cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY):
an open-label,
randomised, non-inferiority clinical trial
|
18.008 |
CYTOCOR |
PROTOCOLO |
Enfermedades Infecciosas |
| 2017 |
Optimisation of empirical
antimicrobial therapy in patients with haematological malignancies and
febrile neutropenia (How
Long study): an open-label, randomised, controlled phase 4 trial
|
15.010 |
HOW LONG |
RESULTADOS |
Enfermedades Infecciosas |
| 2017 |
Targeted simplification
versus antipseudomonal broad-spectrum betalactams in patients with
bloodstream infections due to
Enterobacteriaceae (SIMPLIFY): a study protocol for a multicentre,
open-label, phase III
randomised, controlled, non-inferiority clinical trial
|
16.001 |
SIMPLIFY |
PROTOCOLO |
Enfermedades Infecciosas |